Immunic (IMUX) News Today $1.18 +0.13 (+12.38%) Closing price 02/20/2025 04:00 PM EasternExtended Trading$1.18 0.00 (0.00%) As of 02/20/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Immunic highlights IMU-856's potential as weight management therapyFebruary 20 at 10:02 AM | proactiveinvestors.comImmunic announces IMU-856 demonstrated dose-dependent increaseFebruary 20 at 8:44 AM | markets.businessinsider.comImmunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical TestingFebruary 20 at 7:30 AM | prnewswire.comImmunic (IMUX) to Release Quarterly Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 20 at 1:10 AM | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Short Interest UpdateImmunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 3,750,000 shares, an increase of 6.5% from the January 15th total of 3,520,000 shares. Based on an average trading volume of 925,600 shares, the short-interest ratio is currently 4.1 days.February 19 at 8:10 AM | marketbeat.comIMUX stock touches 52-week low at $0.92 amid market challengesFebruary 12, 2025 | msn.comAnalysts Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $12.67February 11, 2025 | americanbankingnews.comImmunic (NASDAQ:IMUX) Rating Lowered to Sell at StockNews.comStockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research note on Monday.February 10, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by BrokeragesShares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have been assigned an average recommendation of "Buy" from the eight ratings firms that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and two have assigned a strFebruary 6, 2025 | marketbeat.comEQS-News: Immunic to Participate in Investor and Scientific Conferences in FebruaryFebruary 4, 2025 | markets.businessinsider.comImmunic to Participate in Investor and Scientific Conferences in FebruaryFebruary 4, 2025 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Sees Significant Growth in Short InterestImmunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 5,640,000 shares, a growth of 14.9% from the December 31st total of 4,910,000 shares. Based on an average daily volume of 976,100 shares, the days-to-cover ratio is presently 5.8 days.February 1, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Immunic from a "sell" rating to a "hold" rating in a research report on Friday.January 31, 2025 | marketbeat.comPromising Outlook for Immunic’s VidoCa in PMS: Favorable Risk/Reward and Key Metrics Drive Buy RatingJanuary 29, 2025 | markets.businessinsider.comImmunic Inc.January 22, 2025 | thestreet.comImmunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in DecemberImmunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 5,640,000 shares, an increase of 14.9% from the December 15th total of 4,910,000 shares. Based on an average trading volume of 976,100 shares, the short-interest ratio is presently 5.8 days.January 19, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of "Buy" from AnalystsShares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have received an average rating of "Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendationJanuary 12, 2025 | marketbeat.comImmunic eyes transformative year ahead for MS therapy vidofludimus calcium - ICYMIJanuary 11, 2025 | proactiveinvestors.comImmunic eyes key data readout from multiple sclerosis trial in 2025January 7, 2025 | proactiveinvestors.comEQS-News: Immunic Highlights 2024 Accomplishments and Upcoming MilestonesJanuary 7, 2025 | markets.businessinsider.comImmunic Highlights 2024 Accomplishments and Upcoming MilestonesJanuary 7, 2025 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from AnalystsShares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have received an average recommendation of "Buy" from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recomDecember 18, 2024 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Sees Large Increase in Short InterestImmunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 4,190,000 shares, an increase of 10.3% from the November 15th total of 3,800,000 shares. Based on an average daily trading volume, of 885,100 shares, the days-to-cover ratio is currently 4.7 days.December 15, 2024 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC lowered its holdings in Immunic, Inc. (NASDAQ:IMUX - Free Report) by 27.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,099,278 shares of the company's stock after selling 1,974,566 shares during the periodDecember 9, 2024 | marketbeat.comB. Riley Estimates Immunic's FY2024 Earnings (NASDAQ:IMUX)Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at B. Riley lowered their FY2024 earnings per share estimates for shares of Immunic in a research note issued to investors on Tuesday, November 26th. B. Riley analyst W. Wood now forecasts that the company will post earnings per share ofNovember 28, 2024 | marketbeat.comAnalysts Offer Predictions for Immunic FY2024 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Immunic in a research report issued on Monday, November 25th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.November 27, 2024 | marketbeat.comEQS-News: Immunic, Inc. to Participate in Investor Conference in DecemberNovember 26, 2024 | markets.businessinsider.comImmunic initiated with a Buy at H.C. WainwrightNovember 26, 2024 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Immunic (IMUX) with Buy RecommendationNovember 26, 2024 | msn.comImmunic’s Promising Pipeline Progress and Stable Financials Justify Buy RatingNovember 26, 2024 | markets.businessinsider.comQ4 Earnings Estimate for Immunic Issued By HC WainwrightImmunic, Inc. (NASDAQ:IMUX - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for Immunic in a research note issued to investors on Monday, November 25th. HC Wainwright analyst M. Caufield forecasts that the company will earn ($0.25) perNovember 26, 2024 | marketbeat.comImmunic, Inc. to Participate in Investor Conference in DecemberNovember 26, 2024 | prnewswire.comHC Wainwright Initiates Coverage on Immunic (NASDAQ:IMUX)HC Wainwright started coverage on shares of Immunic in a report on Monday. They set a "buy" rating and a $10.00 price objective for the company.November 25, 2024 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from BrokeragesShares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation and two have given a strong buy rNovember 23, 2024 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)November 19, 2024 | markets.businessinsider.comImmunic's IMU-856 shows potential in gastrointestinal health trials - ICYMINovember 16, 2024 | proactiveinvestors.comRichard Alan Rudick Acquires 87,300 Shares of Immunic, Inc. (NASDAQ:IMUX) StockNovember 14, 2024 | insidertrades.comImmunic announces publication of IMU-856 dataNovember 13, 2024 | markets.businessinsider.comImmunic reports positive Phase 1 results for celiac disease therapy published in The LancetNovember 13, 2024 | proactiveinvestors.comImmunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & HepatologyNovember 13, 2024 | prnewswire.comOptimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCaNovember 13, 2024 | markets.businessinsider.comImmunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial ChallengesNovember 9, 2024 | finance.yahoo.comImmunic, Inc. (IMUX) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comEQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 8, 2024 | markets.businessinsider.comImmunic, Inc. Advances MS Trials Amid Financial UpdateNovember 8, 2024 | markets.businessinsider.comImmunic highlights progress in multiple sclerosis programs, targets 2025 milestonesNovember 7, 2024 | proactiveinvestors.comImmunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comImmunic Q3 2024 Earnings PreviewNovember 7, 2024 | msn.comImmunic (IMUX) to Release Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comImmunic (IMUX) Scheduled to Post Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.com Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUX Media Mentions By Week IMUX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.590.60▲Average Medical News Sentiment IMUX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼63▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tourmaline Bio News MBX Biosciences News Aurora Cannabis News Terns Pharmaceuticals News Foghorn Therapeutics News Taysha Gene Therapies News Cryoport News Annexon News Corvus Pharmaceuticals News Trevi Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
